Brief: Biomarin Pharmaceutical Q3 EPS USD 0.55
29/10/2024 20:03
Oct 29 (Reuters) - Biomarin Pharmaceutical Q3 revenue USD 746 million vs. IBES estimate USD 700.1 million. * Q3 net income USD 106 million vs. IBES estimate USD 103.4 million * Q3 basic EPS USD 0.56 * Q3 adjusted EPS USD 0.91 vs. IBES estimate USD 0.52
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife